| Properties | Information | |
|---|---|---|
| PhytoCAT-ID | PhytoCAT-372 | |
| Phytochemical name or plant extracts | Hyperelodiones C | |
| PMID | 31841782 | |
| Literature evidence | Thus, hyperelodione C can be considered as a promising lead compound for cancer therapy, which can bind to RXRα-LBD and induce HeLa and MCF-7 cell apoptosis. | |
| IUPAC name | NA | |
| Phytochemicals’ class or type of plant extracts | Monoterpenoid | |
| Source of phytochemicals or plant Extracts | Hypericum elodeoides | |
| Geographical availability | Assam, China South-Central, China Southeast, East Himalaya, Myanmar, Nepal, Tibet, West Himalaya | |
| Plant parts | Whole plant | |
| Other cancers | Breast cancer, Cervical cancer | |
| Target gene or protein | NA | |
| Gene or Protein evidence | NA | |
| Target pathways | NA | |
| IC50 | 26.33 μΜ against MCF-7 | |
| Potency | Among them, compound 3 showed the most potent growth inhibitory effects on the HeLa and MCF-7 cell lines with IC50 values of 24.39 and 26.33 μΜ, respectively. Thus, hyperelodione C can be considered as a promising lead compound for cancer therapy, which can bind to RXRα-LBD and induce HeLa and MCF-7 cell apoptosis. | |
| Cell line/ mice model | HeLa, MCF-7 | |
| Additional information | In addition, hyperelodiones A-C dose-dependently inhibited RXRα transactivation and the growth of HeLa and MCF-7 cells. | |
| PubChem ID | NA | |
| Additional PMIDs | NA | |
| Additional sources of information | https://powo.science.kew.org/taxon/urn:lsid:ipni.org:names:433398-1 | |
| Safety | NA |